IP40 Stock Chart & Stats
€1.48
€0.00(0.00%)
At close: 4:00 PM EDT
€1.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.10 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)159.00
Market Cap
€5.49M
Enterprise Value€8.16M
Total Cash (Recent Filing)€6.44M
Total Debt (Recent Filing)€1.66M
Price to Earnings (P/E)―
Beta-0.44
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding4,498,772
10 Day Avg. Volume39
30 Day Avg. Volume159
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margin near 90% indicates favorable economics on products already being sold and provides substantial room to cover operating expenses. If maintained, this margin profile can support reinvestment in cannabinoid delivery platforms and improve future profitability as revenue stabilizes.
Moderate LeverageModerate debt relative to equity and a positive equity base provide some financial support while the company works toward profitability. This balance-sheet position is more resilient than a highly leveraged structure and may preserve flexibility for product development and commercialization.
Narrowing LossesThe substantial reduction in losses over prior years suggests progress toward a more sustainable operating model, even though profitability has not yet been reached. Continued improvement could reduce future funding pressure and allow the company to convert strong gross margins into positive earnings.
Bears Say
Declining Revenue And LossesFalling revenue combined with a negative net margin shows that the current business is not yet producing profitable growth. Without renewed demand or successful commercialization of its pipeline, weaker scale can prolong operating losses and limit internally funded investment.
Persistent Cash BurnNegative operating and free cash flow means the company is consuming cash rather than funding operations internally. The shift from positive cash flow in 2025 to current burn raises the prospect of additional financing needs and increases execution pressure over the coming quarters.
Rising Leverage And Negative ROEAlthough leverage remains moderate, its upward direction alongside negative returns on equity signals that borrowed capital is not yet generating adequate shareholder returns. If losses and cash burn persist, rising debt could narrow financial flexibility and increase funding risk.
InnoCan Pharma News
IP40 FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was €1.10 and its highest was €11.80 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is €5.49M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Dec 02, 2026 which is in 34 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -€0.006 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went up 5.396%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in DE:IP40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.